Role of active surveillance and focal therapy in low- and intermediate-risk prostate cancers - Abstract

PURPOSE: Low-risk prostate cancer is found in about half of newly diagnosed men subjected to PSA screening.

METHODS: To define the role of active surveillance and focal therapy in low- and intermediate-risk prostate cancers, an invited international panel of practicing physicians in the field of localized prostate cancer discussed the available literature in three consecutive meetings to come to a broad interpretation of the available data.

RESULTS: The panel ("new prostate cancer management group," npm) agreed on the following observations. In most men with a low-volume Gleason 6 tumor, initial conservative management is appropriate. In men with a larger unifocal Gleason score 6 or 3 + 4 lesion, focal therapy, although still considered an investigational approach, appears to be a suitable option in early non-randomized comparison studies. Furthermore, in patients with multifocal small satellite Gleason 6 lesions in the presence of a larger index lesion, focal therapy of the index lesion is an option. For patients with high-grade, large-volume disease, or in young men with evidence of high-volume multifocal low-grade prostate cancer, whole-gland treatment should be considered.

CONCLUSION: Active surveillance is a preferred and safe option for low-risk prostate cancer. Focal therapy is still under investigation, but the available phase II data are promising. Clinical benefits must be shown in prospective trials. With improved imaging, focal therapy may be an option for patients not choosing active surveillance with low-risk disease, progression upon active surveillance or intermediate-risk cancers with a localizable lesion.

Written by:
van der Poel H, Klotz L, Andriole G, Azzouzi AR, Bjartell A, Cussenot O, Hamdy F, Graefen M, Palma P, Rivera AR, Stief CG.   Are you the author?
Department of Urology, Netherlands Cancer Institute, Amsterdam, The Netherlands.  


Reference: World J Urol. 2015 Jul;33(7):907-16.
doi: 10.1007/s00345-015-1603-7

PubMed Abstract
PMID: 26037891 Prostate Cancer Section